Peptide Research Library

Broad tissue repair, gut healing, and tendon regeneration. The most studied recovery peptide.

Thymosin Beta-4 fragment. Systemic healing via actin upregulation and angiogenesis.

Copper-binding tripeptide. Collagen synthesis, wound repair, and anti-aging skin research.

Thymus-derived immune modulator with antiviral and anti-tumor research. Approved in some countries.

HGH fragment (176–191) studied for fat metabolism without IGF-1 or glucose effects.

Human cathelicidin antimicrobial peptide. Innate immunity, wound healing, and anti-biofilm research.

Alpha-MSH-derived tripeptide. Potent anti-inflammatory effects studied in gut disease, wound healing, and skin conditions.

Selective GHRP. Clean GH pulse with no meaningful cortisol or prolactin elevation.

GHRH analogue. Amplifies GH pulse duration. Almost always paired with Ipamorelin.

First 29 amino acids of endogenous GHRH. More physiological than synthetic GHRPs.

FDA-approved GHRH analogue (Egrifta). Clinical data on visceral fat reduction.

Second-generation GHRP. Potent GH release with some cortisol and prolactin elevation.

First widely studied GHRP. Strong GH pulse; notable hunger side effect via ghrelin.

Most potent GHRP. Significant GH release with cardiac protective effects independent of GH.

FDA-approved GLP-1 agonist (Ozempic/Wegovy). ~15–17% average weight loss in trials.

Dual GIP/GLP-1 agonist (Mounjaro/Zepbound). Up to 21% weight loss in SURMOUNT trials.

Daily GLP-1 agonist (Victoza/Saxenda). Longest safety track record in the GLP-1 class.

Triple GLP-1/GIP/glucagon agonist in trials. Up to 24% weight loss in Phase 2 data.

Long-acting IGF-1 analogue. Muscle satellite cell activation and protein synthesis.

Mechano Growth Factor — IGF-1 splice variant expressed in response to mechanical stress.

Endogenous myostatin inhibitor. Muscle hypertrophy research via activin blockade.

Pineal tetrapeptide. Telomerase activation and telomere extension research.

Mitochondria-derived peptide. Neuroprotection, anti-apoptosis, and age-related disease research.

Mitochondrial peptide with exercise-mimetic and insulin-sensitizing properties.

Mitochondria-targeting peptide (Elamipretide). Heart failure and oxidative stress research.

ERRα agonist and exercise mimetic. Activates mitochondrial biogenesis pathways that mimic endurance training.

ACTH-derived nootropic. Rapid BDNF and NGF upregulation. Neuroprotection in Russian trials.

Anxiolytic without sedation or dependence. Tuftsin analogue with cognitive enhancement data.

HGF potentiator. Potentially the most potent cognitive-enhancing peptide identified to date.

Vasoactive Intestinal Peptide. Anti-inflammatory, immune modulating, and CIRS protocol research.

Pineal tripeptide. Neuroprotection and circadian rhythm regulation from Khavinson research group.

FDA-approved bremelanotide (Vyleesi). Central nervous system mechanism for sexual dysfunction.

Non-selective melanocortin agonist. Tanning, libido, appetite suppression — broad side effect profile.

Selective MC1R agonist (Afamelanotide/Scenesse). FDA-approved tanning without libido effects.

GnRH regulator. Hormone axis support, LH/FSH modulation, and fertility research.

Delta Sleep-Inducing Peptide. Sleep architecture improvement and cortisol modulation research.

Thymic peptide extract. Immune restoration and longevity data from Russian clinical studies.